‘Celltrion’ becomes top in spending R&D expenses
The KOSDAQ listed pharmaceutical companies’ average R&D expense/sales rate in the 3rd quarter exceeded 10%, and the one for KOSPI listed pharmaceutical companies did not reach 10%.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the 37 KOSPI and 29 KOSDAQ listed pharmaceutica...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
